Capital Performance Advisors’s Regenxbio RGNX Stock Holding History

Capital Performance Advisors’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11	Closed	-$115	–	2115
2024 Q3	$115	Buy	+11	New	+$134	﹤0.01%	2671

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Performance Advisors's RGNX Position: Q4 2024 in Review

Capital Performance Advisors sold out of Regenxbio (RGNX) in Q4 2024, closing a stake of 11 shares — an estimated $115 sold.

Capital Performance Advisors first reported a position in RGNX in Q3 2024 and held it in 1 quarter. The position peaked at $115 in Q3 2024. 177 funds tracked by Wall St. Rank hold RGNX as of Q4 2024.

Capital Performance Advisors reported no remaining Regenxbio position as of Q4 2024 after selling out during the quarter.
Capital Performance Advisors sold 11 Regenxbio shares in Q4 2024, an estimated $115.
Capital Performance Advisors first reported a position in Regenxbio in Q3 2024 and held it in 1 quarter.
Capital Performance Advisors's Regenxbio position peaked at $115 in Q3 2024.
177 funds tracked by Wall St. Rank held Regenxbio as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.